Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (71-80 of 146) with videos related to

Pageof 15
Sort By:
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|May 22, 2009
[A case of cavitating pneumococcal pneumonia developed during the treatment with etanercept for rheumatoid arthritis]Yoko Kida, Yuka Harada, Ryo Tachikawa, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2024
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-studyAkito Hata, Nobuyuki Katakami, Naoto Takase, et al.
Cancer Management and Research|September 20, 2019
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyMotoko Tachihara, Tatsunori Kiriu, Akito Hata, et al.
Bioorganic & Medicinal Chemistry|April 11, 2017
Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potentialJun Fujimoto, Takaharu Hirayama, Yasuhiro Hirata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2011
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]Akito Hata, Nobuyuki Katakami, Yoshio Masuda, et al.
Oncotarget|November 10, 2018
Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)Yoshihiro Hattori, Miyako Satouchi, Nobuyuki Katakami, et al.
Anticancer Research|January 31, 2021
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR MutationHiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2012
[Cisplatin administration for outpatients with short hydration of less than four hours]Akito Hata, Nobuyuki Katakami, Yoshio Masuda, et al.
Lung Cancer (Amsterdam, Netherlands)|September 11, 2010
Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancerAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Pageof 15

Showing results (71-80 of 146) with videos related to

Sort By:
Pageof 15
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|May 22, 2009
[A case of cavitating pneumococcal pneumonia developed during the treatment with etanercept for rheumatoid arthritis]Yoko Kida, Yuka Harada, Ryo Tachikawa, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2024
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-studyAkito Hata, Nobuyuki Katakami, Naoto Takase, et al.
Cancer Management and Research|September 20, 2019
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyMotoko Tachihara, Tatsunori Kiriu, Akito Hata, et al.
Bioorganic & Medicinal Chemistry|April 11, 2017
Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potentialJun Fujimoto, Takaharu Hirayama, Yasuhiro Hirata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2011
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]Akito Hata, Nobuyuki Katakami, Yoshio Masuda, et al.
Oncotarget|November 10, 2018
Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)Yoshihiro Hattori, Miyako Satouchi, Nobuyuki Katakami, et al.
Anticancer Research|January 31, 2021
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR MutationHiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2012
[Cisplatin administration for outpatients with short hydration of less than four hours]Akito Hata, Nobuyuki Katakami, Yoshio Masuda, et al.
Lung Cancer (Amsterdam, Netherlands)|September 11, 2010
Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancerAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Pageof 15